Da Silva et al. (Da Silva et al., 2019) used PLGA nanoparticles as delivery vehicles for the co-delivery of three immune adjuvants [the TLR3 agonist Poly (I:C;pIC), TLR7/8 agonist Resiquimod (R848) and the chemokine Macrophage Inflammatory Protein-3 alpha (MIP3α)] to significantly improve the therapeutic efficacy of cancer vaccines. This evidence concerns the gene CCL20 and cancer.